{"nctId":"NCT00918580","briefTitle":"Study Evaluating 13-valent Pneumococcal Conjugate Vaccine (13vPnC) in Children With Sickle Cell Disease","startDateStruct":{"date":"2009-11"},"conditions":["Pneumococcal Conjugate Vaccine"],"count":158,"armGroups":[{"label":"1","type":"EXPERIMENTAL","interventionNames":["Biological: 13-valent Pneumoccocal Conjugate Vaccine"]}],"interventions":[{"name":"13-valent Pneumoccocal Conjugate Vaccine","otherNames":["13vPnC"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Male or female subject between the ages of \\>=6 to \\<18 years.\n* Diagnosis of SCD\n* 23vPS vaccination at least 6 months prior to enrollment.\n\nExclusion Criteria:\n\n* Previous vaccination with pneumococcal conjugate vaccine.\n* Previous reaction to any vaccine or vaccine-related component or contraindication to vaccination with pneumococcal conjugate vaccine.","healthyVolunteers":false,"sex":"ALL","minimumAge":"6 Years","maximumAge":"17 Years","stdAges":["CHILD"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Geometric Mean Fold Rise (GMFR) in Serotype-Specific Pneumococcal Immunoglobulin G (IgG) From 1 Month After 13vPnC Dose 1 to 1 Month After 13vPnC Dose 2","description":"GMFR for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) from 1 month after 13vPnC Dose 1 to 1 month after 13vPnC Dose 2 were computed using the logarithmically transformed assay results. Confidence interval (CI) for GMFR were back transformations of a CI based on the Student t distribution for the mean logarithm of the mean fold rise. GMFRs were calculated using all participants with available data from both 1 month after 13vPnC Dose 1 and after 13vPnC Dose 2 blood draws. Here number of participants analyzed signifies the evaluable immunogenicity population and \"N\" signifies participants with a determinate IgG antibody concentration for the given serotype at both 1 Month After 13vPnC Dose 1 and 1 Month After 13vPnC Dose 2 blood draws. Participants may be represented in more than 1 category.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.75","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.89","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.82","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.75","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.70","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.05","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.91","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.88","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.82","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.90","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.95","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.75","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.83","spread":null}]}]}]},{"type":"SECONDARY","title":"Geometric Mean Fold Rise (GMFR) in Serotype-Specific Pneumococcal Immunoglobulin G (IgG) From Before 13vPnC Dose 1 to 1 Month After 13vPnC Dose 1","description":"GMFR for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) from before 13vPnC Dose 1 to 1 month after 13vPnC Dose 1 were computed using the logarithmically transformed assay results. CI for GMFR were back transformations of a CI based on the Student t distribution for the mean logarithm of the mean fold rise. GMFRs were calculated using all participants with available data from before 13vPnC Dose 1 and 1 month after 13vPnC Dose 1 blood draws. Here number of participants analyzed signifies the evaluable immunogenicity population and \"N\" signifies participants with determinate IgG antibody concentration for the given serotype at both the before 13vPnC Dose 1 and 1 month after 13vPnC Dose 1 blood draws. Participants may be represented in more than 1 category.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.91","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.72","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.10","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.50","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.58","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.76","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.58","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.60","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.03","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.74","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.10","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.38","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.28","spread":null}]}]}]},{"type":"SECONDARY","title":"Geometric Mean Fold Rise (GMFR) in Serotype-Specific Pneumococcal Immunoglobulin G (IgG) From Before 13vPnC Dose 2 to 1 Month After 13vPnC Dose 2","description":"GMFR for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) from before 13vPnC Dose 2 to 1 month after 13vPnC Dose 2 were computed using the logarithmically transformed assay results. CI for GMFR were back transformations of a CI based on the Student t distribution for the mean logarithm of the mean fold rise. GMFRs were calculated using all participants with available data from before 13vPnC Dose 2 and 1 month after 13vPnC Dose 2 blood draws. Here number of participants analyzed signifies the evaluable immunogenicity population and \"N\" signifies participants with determinate IgG antibody concentration for the given serotype at both the before 13vPnC Dose 2 and 1 month after 13vPnC Dose 2 blood draws. Participants may be represented in more than 1 category.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.86","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.80","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.48","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.24","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.47","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.08","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.04","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.73","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.36","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.30","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.80","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.75","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.48","spread":null}]}]}]},{"type":"SECONDARY","title":"Ratio of Geometric Mean Fold Rise (GMFR) in Serotype-Specific Pneumococcal Immunoglobulin G (IgG) From 13vPnC Dose 1 to 13vPnC Dose 2","description":"GMFR for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) were computed using the logarithmically transformed assay results for Dose 1 (after Dose 1/before Dose 1) and for Dose 2 (after Dose 2/before Dose 2). CI for the ratio of GMFR (Dose 2/Dose 1) were back transformations of a CI based on the Student t distribution for the mean logarithm of the measures (Dose 2 - Dose 1). Here number of participants analyzed signifies the evaluable immunogenicity population and \"N\" signifies participants with determinate IgG antibody concentration for given serotype at before 13vPnC Dose 1, 1 month after 13vPnC Dose 1, before 13vPnC Dose 2 and 1 month after 13vPnC Dose 2 blood draws. Participants may be represented in more than 1 category.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.26","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.38","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.49","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.22","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.26","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.44","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.32","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.47","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.66","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.75","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.45","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.39","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.45","spread":null}]}]}]},{"type":"SECONDARY","title":"Geometric Mean Concentration (GMC) for Serotype-Specific Pneumococcal Immunoglobulin G (IgG) Antibody","description":"Antibody GMC for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) are presented. GMC (13vPnC) and corresponding 2-sided 95 percent (%) CIs were evaluated. Geometric means were calculated using all participants with available data for the specified blood draw. CI for GMC were back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations. Here number of participants analyzed signifies the evaluable immunogenicity population and \"N\" signifies participants with determinate IgG antibody concentration for the given serotype at specified time point. Participants may be represented in more than 1 category.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.01","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.79","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.01","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.30","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.40","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.46","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.80","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.57","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.02","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.14","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.62","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.16","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.16","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.85","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"27.25","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.31","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"34.63","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.83","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"20.40","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"18.25","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.24","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.04","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.19","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17.61","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.46","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"26.82","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.77","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13.67","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.19","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"21.07","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.73","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10.34","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.07","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.65","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.27","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.91","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.05","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.09","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15.13","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.09","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"24.52","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.46","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"26.19","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.44","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"20.56","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16.18","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.51","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.67","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.33","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16.37","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.06","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"22.19","spread":null}]}]}]},{"type":"SECONDARY","title":"Geometric Mean Concentration (GMC) for Serotype-Specific Pneumococcal Immunoglobulin G (IgG) Antibody 1 Year After 13vPnC Dose 2","description":"Antibody GMC for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) are presented. GMC (13vPnC) and corresponding 2-sided 95 percent (%) CIs were evaluated. Geometric means were calculated using all participants with available data for the specified blood draw. CI for GMC were back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations. Here number of participants analyzed signifies the evaluable immunogenicity population at 1-year follow-up and \"N\" signifies participants with determinate IgG antibody concentration for the given serotype. Participants may be represented in more than 1 category.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.94","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.77","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.50","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15.89","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.64","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.87","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.70","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.12","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.01","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.38","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.94","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.47","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13.30","spread":null}]}]}]},{"type":"SECONDARY","title":"Serotype-Specific Pneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMT)","description":"Antibody GMTs as measured by OPA assay for 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F). GMT and corresponding 2-sided 95% CIs were evaluated. CIs for the GMTs are back transformations of a confidence interval based on the Student t distribution for the mean logarithm of the titers. GMTs were calculated using all participants with available data for the specified blood draw. Here number of participants analyzed signifies the evaluable immunogenicity population and \"N\" signifies participants with determinate OPA antibody titer for the given serotype at specified time point. Participants may be represented in more than 1 category.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"215","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"626","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"234","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"628","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"426","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"94","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"34","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"246","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"344","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"137","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2670","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7535","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2312","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2288","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4326","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1429","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1607","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"56","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"115","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"277","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7845","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3348","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1449","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1331","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4174","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1445","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1652","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1928","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"516","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"897","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"23","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"56","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"98","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4005","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1791","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"677","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3051","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7601","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3467","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2081","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5271","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1507","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2330","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"78","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"105","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"273","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7633","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3723","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1314","spread":null}]}]}]},{"type":"SECONDARY","title":"Serotype-Specific Pneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMT) 1 Year After 13vPnC Dose 2","description":"Antibody GMTs as measured by OPA assay for 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F). GMT and corresponding 2-sided 95% CIs were evaluated. CIs for the GMTs are back transformations of a confidence interval based on the Student t distribution for the mean logarithm of the titers. GMTs were calculated using all participants with available data for the specified blood draw. Here number of participants analyzed signifies the evaluable immunogenicity population at 1-year follow-up and \"N\" signifies participants with determinate OPA antibody titer for the given serotype. Participants may be represented in more than 1 category.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1107","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3412","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1690","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1595","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1604","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"620","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"924","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"25","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"31","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"102","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2485","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2166","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"589","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Percentage of Participants With Prespecified Local Reactions: 13vPnC Dose 1","description":"Specific local reactions were prompted for each day, and reported using an electronic diary. Redness and Swelling were scaled as: Any (redness present or swelling present); Mild (less than \\<2.5 centimeters \\[cm\\] for participants aged 6 to \\<12 years and 2.5 to 5.0 cm for participants aged greater than or equal to \\[\\>=\\] 12 years); Moderate (2.5 to 7.0 cm for participants aged 6 to \\<12 years and 5.1 to 10.0 cm for participants aged \\>=12 years); Severe (\\>7 cm for participants aged 6 to \\<12 years and \\>10 cm for participants aged \\>=12 years). Pain was scaled as: Any (pain present); Mild (did not interfere with activity); Moderate (interfered with activity); Severe (prevented daily activity). Here \"Number of participants analyzed\" signifies the safety population for Dose 1 and \"N\" signifies those participants who reported \"Yes\" for at least 1 day or \"No\" for all days for specified local reaction. Participants may be represented in more than 1 category.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"89.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"81.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"56.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"23.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"20.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"49.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"37.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"26.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.1","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Percentage of Participants With Prespecified Local Reactions: 13vPnC Dose 2","description":"Specific local reactions were prompted for each day, and reported using an electronic diary. Redness and Swelling were scaled as: Any (redness present or swelling present); Mild (\\<2.5 cm for participants aged 6 to \\<12 years and 2.5 to 5.0 cm for participants aged \\>=12 years); Moderate (2.5 to 7.0 cm for participants aged 6 to \\<12 years and 5.1 to 10.0 cm for participants aged \\>=12 years); Severe (\\>7 cm for participants aged 6 to \\<12 years and \\>10 cm for participants aged \\>=12 years). Pain was scaled as: Any (pain present); Mild (did not interfere with activity); Moderate (interfered with activity); Severe (prevented daily activity). Here number of participants analyzed signifies the safety population for Dose 2 and \"N\" signifies those participants who reported \"Yes\" for at least 1 day or \"No\" for all days for specified local reaction. Participants may be represented in more than 1 category.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"85.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"77.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"53.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"26.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"53.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"37.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"35.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Percentage of Participants With Prespecified Systemic Events: 13vPnC Dose 1","description":"Specific systemic events (fever \\>=38 degrees Celsius\\[C\\], vomiting, diarrhea, headache, fatigue, muscle pain, joint pain, use of antipyretic medications) were prompted for each day and reported using an electronic diary. Fatigue, headache, muscle pain and joint pain were scaled as: Any(symptom present); Mild(did not interfere with activity); Moderate(some interference); Severe(prevented routine daily activity). Vomiting was scaled as: Any(vomiting present); Mild(1-2 times in 24 hours); Moderate(\\>2 times in 24 hours); Severe(required intravenous hydration). Diarrhea was scaled as: Any(diarrhea present); Mild(2-3 loose stools in 24 hours);Moderate(4-5 loose stools 24 hours); Severe(\\>=6 loose stools in 24 hours). Here number of participants analyzed signifies the safety population for Dose 1 and \"N\" signifies those participants who reported \"Yes\" for at least 1 day or \"No\" for all days for specified systemic event. Participants may be represented in more than 1 category.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"53.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"42.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"34.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"66.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"48.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"44.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"74.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"58.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"47.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"39.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"23.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"23.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"58.2","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Percentage of Participants With Prespecified Systemic Events: 13vPnC Dose 2","description":"Specific systemic events (fever \\>=38 degrees C, vomiting, diarrhea, headache, fatigue, muscle pain, joint pain, and use of antipyretic medications) were prompted for each day, and reported using an electronic diary. Fatigue, headache, muscle pain and joint pain were scaled as: Any(symptom present); Mild(did not interfere with activity); Moderate(some interference); Severe(prevented routine daily activity). Vomiting was scaled as: Any(vomiting present); Mild(1-2 times in 24 hours); Moderate(\\>2 times in 24 hours); Severe (required intravenous hydration). Diarrhea was scaled as: Any(diarrhea present); Mild(2-3 loose stools in 24 hours); Moderate(4-5 loose stools 24 hours); Severe(\\>=6 loose stools in 24 hours). Here number of participants analyzed signifies the safety population for Dose 2 and \"N\" signifies those participants who reported \"Yes\" for at least 1 day or \"No\" for all days for specified systemic event. Participants may be represented in more than 1 category.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"25.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"19.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"59.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"41.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"36.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"62.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"48.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"41.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"75.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"60.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"45.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"44.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"34.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"21.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"43.6","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":40,"n":158},"commonTop":["Pain (Any)","Pain (Mild)","Muscle pain (Any)","Fatigue (Any)","Muscle pain (Mild)"]}}}